BACKGROUND : We recently identified 156 proteins in human plasma that were each associated with the net Framingham Cardiovascular Disease Risk Score using an aptamer-based proteomic platform in Framingham Heart Study Offspring participants. Here we hypothesized that performing genome-wide association studies and exome array analyses on the levels of each of these 156 proteins might identify genetic determinants of risk-associated circulating factors and provide insights into early cardiovascular pathophysiology.
C
irculating proteins are key effectors and markers of cardiovascular disease (CVD). An emerging, highly multiplexed, aptamer-based proteomic technology 1, 2 has recently allowed for the systematic profiling of 1129 protein levels in plasma samples from the Framingham Heart Study (FHS) Offspring cohort. 3 In addition to confirming established CVD pathways, these analyses identified many proteins with novel associations to cardiometabolic traits and vascular disease, including aminoacylase-1, Dickkopf-related protein 3, and WFKN2. Overall, 156 proteins were identified that each had strong associations with the net Framingham CVD Risk Score (Bonferroni-adjusted P≤4.4×10 -5 ). The integration of genomic data with protein and metabolite levels in human blood samples can provide valuable insight into key genomic loci that influence levels of disease-associated circulating factors. 2 These quantitative trait loci (QTLs) often have substantial effect sizes and point toward molecular mechanisms that directly influence the disposition of intermediate phenotypes. For example, QTLs have been identified that link plasma metabolite levels directly to upstream or downstream enzymes or transporters. 4, 5 Genetic associations help illuminate novel biological pathways that underlie protein and metabolite regulation-and may ultimately link genetic risk loci to clinical phenotypes. These correlations additionally provide powerful tools to study genetic loci of interest that have been robustly identified in large-scale, consortium-based genome-wide association study (GWAS) meta-analyses. Disease-associated genetic variants are often located in noncoding regions of the genome. 6 Characterizing the functional consequence of human variants on protein levels can help map loci and identify causal genes in disease pathophysiology. Finally, tying genetic risk loci to plasma protein levels may serve as a powerful strategy to identify circulating proteins that can be used as biomarkers in clinical CVD.
Here we defined the genetic architecture of 156 plasma proteins associated with the Framingham CVD Risk Score (FRS) in FHS Offspring participants with validation in individuals in the MDCS (Malmö Diet and Cancer Study). By leveraging the family-based structure of FHS, we examined the relative contributions of genetic versus clinical factors on interindividual variability of protein levels. We also examined the relative influences of cis versus trans relationships between genetic variants and the coding gene for measured circulating proteins. Interestingly, several of the identified protein quantitative trait loci (pQTLs) overlapped with known CVD risk loci from large-scale GWASs and pointed toward novel mechanisms of proteomic regulation in plasma. In addition to focusing on pQTLs strongly associated with individual proteins, we studied whether certain loci might have pleiotropic effects on the levels of multiple circulating CVD risk-related proteins. We experimentally validated 1 association of particular interest between plasma levels of apolipoprotein E (ApoE) and phosphatase 1G (PPM1G), a regulator of transcription elongation. 7 Finally, we have made genetic association data for all 156 plasma CVD risk proteins available as a public resource for future cardiometabolic research.
METHODS

Data Sharing
Aptamer-based proteomic profiling, genome-wide genotyping, and exome array genotyping results for all 156 plasma CVD risk proteins measured in FHS have been deposited in the database of Genotypes and Phenotypes. 8 All other results and analytic methods are available within the manuscript or from the authors on request. Details of all commercially available study materials are included throughout the manuscript. Noncommercial study materials will be made available to other researchers for the purposes of reproducing the results or replication of the procedure, as respective Institutional Review Board and Material Transfer Agreements permit.
Study Samples
The FHS Offspring cohort is a community-based, prospective, observational cohort comprising adult children of original FHS participants and spouses of these children who were recruited in 1971 and followed with serial exams. 9 Proteomic profiling
Clinical Perspective
What Is New?
• We recently identified a signature of 156 circulating proteins in human plasma that were each strongly associated with the net Framingham Risk Score of developing cardiovascular disease.
• As a strategy to identify the potential genetic determinants and biological pathways that may regulate the levels of these risk-associated proteins, we integrated genomics and proteomics profiling data from individuals in 2 population-based studies.
• We discovered dozens of novel genetic variants that were each strongly associated with circulating levels of Framingham Risk Score-associated proteins.
What Are the Clinical Implications?
• We highlight numerous examples of how these novel gene locus-protein associations provide new insight into cardiovascular disease risk pathophysiology, including a novel pathway by which the gene phosphatase 1G modulates circulating levels of apolipoprotein E, a key regulator of cholesterol handling.
• Our data suggest that this integrative approach has the potential to identify new biological pathways for biomarker discovery and pharmacological targeting in early cardiovascular disease. 
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was previously performed on baseline plasma samples of 899 participants from a case-cohort design sampling of 311 individuals who attended the fifth examination (1991) (1992) (1993) (1994) (1995) and developed incident CVD and 588 randomly selected individuals who attended the fifth examination and remained free of incident CVD. 3 Incident CVD included coronary heart disease, myocardial infarction, angina, coronary insufficiency, cerebrovascular accident, atherothrombotic infarction of the brain, transient ischemic attack, cerebrovascular disease, and intermittent claudication. Participants with prevalent CVD at the fifth examination were excluded.
The MDCS is a Swedish population-based, prospective, observational cohort recruited between 1991 and 1996. 10 Six hundred fifty-one baseline plasma samples were analyzed from 2 nested case-control samples, including 326 individuals of whom 163 developed incident diabetes mellitus and 163 were sex-specific, propensity-matched (age, body mass index [BMI] , fasting glucose, and hypertension) controls who remained free of diabetes mellitus, as well as 325 individuals of whom 162 developed incident CVD and 163 were sex-specific controls matched by age (±1 year) and FRS (<0.1% difference in 10-year estimated risk). Participants with prevalent CVD or diabetes mellitus were excluded. In all, 1010 baseline plasma samples were additionally analyzed from case-cohort samples, including 584 randomly selected controls and case groups with incident CVD, heart failure, and valvular heart disease.
The study protocols were approved by the Institutional Review Boards of Boston University Medical Center, Beth Israel Deaconess Medical Center, and Lund University, Sweden, and all participants provided written informed consent.
Proteomic Profiling
Proteomic profiling was previously performed as described. 3 Briefly, peripheral blood samples were collected in either citrate-(available in FHS samples) or EDTA-treated tubes (available for MDCS), samples were centrifuged within 15 minutes at 2000g for 10 minutes to pellet cellular elements, and the supernatant plasma was aliquoted and frozen at −80°C. Proteomic profiling was performed using the SOMAscan single-stranded DNA aptamer-based platform (1129 aptamer assay in FHS and 1310 aptamer assay in MDCS). 1 All assays were performed using SOMAscan reagents according to the manufacturer's detailed protocol. From 899 FHS samples and 1661 MDCS samples that were run on the proteomics platform, 9 FHS and 0 MDCS samples fell outside of the acceptable standardization criteria as prespecified by the manufacturer and were excluded from the study. Variations in sample standardization can be caused by sample handling (eg, during pipetting or sample leakage during the hybridization process) or sample content (eg, lipidacious material can interfere with the initial filtering of the sample while hemolytic material can affect the hybridization readout). Of the 890 FHS samples with acceptable proteomics data, 759 had available GWAS data, and 746 had available exome array data. Of the 1661 MDCS samples with acceptable proteomics data, 1421 had corresponding GWAS and exome array data available. The median intraassay coefficients of variation (CVs) were calculated from inclusion of replicated pooled plasma calibrator samples on each assay plate and were ≈8.2% across the 43 FHS plates (24-well format) and ≈2.6% across the 22 MDCS plates (96-well format).
Median interassay CVs were calculated using replicate quality control plasma samples included across all study plates and were 7.8% for FHS samples and 4.2% for MDCS samples. Reproducibility was also analyzed by measuring blinded duplicate samples from 94 FHS Offspring examination 5 participants (N=188 samples, collected between 1991-1995). The median intraclass correlation for 1129 measured proteins was >0.95.
Genome-Wide Genotyping and Imputation
Genome-wide genotyping methods for the FHS have been described previously. 11 Briefly, genotyping was conducted using the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused molecular inversion probes supplemental array. Genotypes were called using Chiamo (http://www. stats.ox.ac.uk/~marchini/software/gwas/chiamo.html). We used the 1000 Genomes Phase I version 3 (August 2012) reference panel to perform imputation using a hidden Markov model implemented in MACH (version 1.0.16) 12 for all single-nucleotide polymorphisms (SNPs) passing the following criteria: call rate ≥97%, P value for the Hardy-Weinberg test statistic (pHWE) ≥1×10 -6 , Mishap P ≥1×10 -9 , Mendel errors ≤100, and minor allele frequency (MAF) ≥1%. In the MDCS, genotyping was conducted using the Illumina Omni Express Exome BeadChip kit. Genotypes were called using Illumina GenomeStudio, and imputation was performed to the same 1000 Genomes version as for FHS using IMPUTE (v2) for SNPs passing the following criteria: call rate ≥95%, pHWE ≥1×10 -6 , and minor allele frequency ≥0.01.
Exome Array
Genotyping of the FHS was performed as previously described. 13 Genotyping was performed using the Illumina Infinium HumanExome BeadChip (version 1.0). Genotype calling was performed centrally using all 62 266 samples from participating studies in the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology).
14 To be included, nonsynonymous, stop-altering, and splice variants needed to be observed ≥2 times in ≥2 datasets. The array additionally included tags for previously described GWAS hits, ancestry informative markers, random synonymous SNPs, mitochondrial SNPs, and human leukocyte antigen tags (http://genome.sph.umich.edu/wiki/Exome_Chip_Design). In sum, >240 000 variants were included on the exome array. Of these variants, 109 911 were polymorphic in the FHS sample, and a further subset of 81 021 variants were nonsynonymous, nonsense, or located in a splice site and had a MAF ≤ 5%.
Statistical Analysis
Because of skewed distributions of most protein levels, association analyses were conducted using inverse normalized transformed values of protein levels. The association of genetic variants and protein levels were tested using linear mixedeffects models to accommodate pedigree structure under an additive genetic model, adjusted for age and sex. GWAS analyses were performed using the R GWAF package, 15 and exome array single-variant analyses were performed using the R seqMeta package. For exome array single-variant analyses, variants with an MAF ≥0.5% that were nonsynonymous, ).
Exome Array Gene-Based Analysis
The effects of single-variant association within a gene were aggregated by summing up the score statistics using a collapsing method as previously described. 16 Briefly, a variant was considered damaging if it was a stop gain/loss, splice-altering, or missense and predicted to be damaging by 2 of the 4 algorithms in the database of human nonsynonymous SNPs and their functional predictions (dbNSFP) (Mutation Taster, Polymorphism Phenotyping version 2 [Polyphen 2 HDIV], sorting intolerant from tolerant, likelihood ratio test). The analysis was carried out using the R seqMeta package across 13 008 genes, and the significance threshold in discovery was adjusted for the number of genes examined (P≤3.8×10 -6 ).
Heritability Analysis
Polygenic heritability of each normalized protein was estimated using variance-component models implemented in SOLAR (Sequential Oligogenic Linkage Analysis), 17 adjusting for all clinical factors. The percentage of interindividual variability explained by each measured clinical factor (partial R 2 ) was assessed by being sequentially added to mixed-effects models in the order of age, sex, smoking status, diabetes mellitus status, high-density lipoprotein cholesterol levels, total cholesterol levels, and systolic blood pressure such that the sum of partial R 2 values was equal to the R 2 of all clinical factors evaluated as a whole. The variance explained by identified association signals was assessed using mixed-effects model adjusting for all clinical factors.
Mendelian Randomization Analyses
To assess for causal associations between circulating plasma proteins and end clinical traits (including the FRS and select risk factors that comprise the FRS), we performed Mendelian randomization analyses 18 using the FHS data. We focused our analyses on sentinel SNPs that explained ≥20% of the variance of the associated circulating plasma protein. Briefly, we calculated the predicted effect size of each sentinel SNP on the end clinical trait as the product of the 2 regression coefficients after regressing the protein level on the SNP and the end clinical trait on the protein level. We then calculated the observed effect size of each sentinel SNP on the end clinical trait by regressing the end clinical trait on the SNP using a 1-sample t test. Causal relationships of proteins on end clinical traits were identified by a significant nonzero observed effect of the SNP on the risk factor (P≤0.05) and a nonsignificant (P≥0.05) difference between the expected and observed effect sizes.
Pathway Enrichment Analyses
Ingenuity Pathway Analysis software (Qiagen) was used to identify enriched pathways among proteins associated with pleiotropic genetic loci.
Overlap Between pQTL and Risk Loci
Overlap between pQTLs and known risk loci were identified using publicly available data from the following large-scale, consortium-based GWAS meta-analyses: coronary artery disease and myocardial infarction risk loci from CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-Wide Replication and Meta-Analysis Plus the Coronary Artery Disease Genetics) data 19 ; DIAGRAM consortium (Diabetes Risk Loci From the Diabetes Genetics Replication and Meta-Analysis) data 20 ; total cholesterol, triglycerides, high-and low-density lipoprotein risk loci from the GLGC (Global Lipids Genetics Consortium) 21 ; and systolic and diastolic blood pressure risk loci from the ICBP (International Consortium for Blood Pressure).
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Tissue Culture Studies
The human liver hepatocellular carcinoma HepG2 cell line (ATCC) was cultured in Eagle's minimal essential medium (Sigma-Aldrich) supplemented with 2 mM glutamine (SigmaAldrich), 1% nonessential amino acids (Sigma-Aldrich), and 10% fetal bovine serum (Gibco Thermo Fisher Scientific) and maintained at 37˚C with 5% carbon dioxide. Ten micromolar PPM1G small-interfering RNA (Thermo Fisher Scientific) or scrambled control small-interfering RNA (Invitrogen) were separately transfected using Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to the manufacturer's standard protocol. For expression studies, cells were incubated for 48 hours, total RNA was isolated using the RNeasy Mini Kit (Qiagen), cDNA was synthesized using the QuantiTect Reverse Transcriptase Kit (Qiagen), and quantitative real-time reversetranscription polymerase chain reactions were performed using SYBR Green probes (Molecular Probes) and quantified using the comparative Ct method. GAPDH was used as the reference gene. Polyubiquitin-C (UBC) was used as a negative control. The sequence of polymerase chain reactions primers was (5ʹ to 3ʹ): PPM1G-For GCTGACTCTCACTGACGACC, PPM1G-Rev GCTCCCCATTTTCATCACGC, GAPDH-For GGGAAGCTTGTCATCAATGGA, GAPDH-Rev TCTCGCTCCT GGAAGATGGT, APOE-For CTGCTCAGCTCCCAGGTC, APOE-Rev TTGTTCCTCCAGTTCCGATT, UBC-For ATTTGGG TCGCGGTTCTTG, UBC-Rev TGCCTTGACATTCTCGATGGT. For secretion assays, culture medium was replaced with fresh medium 48 hours after transfection, and this was then collected 4 hours later and used to measure ApoE and migration inhibitory factor levels by ELISA (R&D Systems) according to the manufacturer's standard protocol.
RESULTS
Heritability Has a Greater Impact Than Clinical Factors on the Variability of Plasma Cardiovascular Disease Risk Proteins
Clinical characteristics of all the human study participants are included in the Table. The family-based structure of the FHS Offspring cohort was leveraged to estimate the relative contributions of heritable fac-
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tors (significant loci from genome-wide profiling) and clinical factors (age, sex, systolic blood pressure, total cholesterol levels, high-density lipoprotein cholesterol levels, smoking status, and diabetes mellitus status) to interindividual variation of plasma CVD risk proteins. As shown in Figure 1 , the proportion of variation for the majority of measured proteins was primarily driven by heritable factors. The proportion of interindividual variance attributable to heritable factors (mean residual polygenic heritability 0.49, SD 0.20) was >3 times that for studied clinical factors (r 2 0.14, SD 0.08). Estimated heritability explained >20% of the interindividual variation for 78 (91.8%) of the 85 proteins with genomewide associations (P≤5×10 -8 ). By contrast, clinical factors explained >20% of interindividual variation for just 14 of these proteins. Heritable factors accounted for up to 88.6% of interindividual variation (eg, tissue factor pathway inhibitor protein). Notably, the 3 individual SNPs with the highest heritability are expression QTL for their corresponding proteins in expression QTL consortium data, suggesting that these associations are independent of aptamer-protein binding properties (Table I in the online-only Data Supplement). Overall, heritability of circulating proteins was higher than for metabolites studied previously in the same cohort (heritability explained >20% of interindividual variation for 66% of 217 measured plasma metabolites). (Figure 3A) . Meta-analysis of the FHS Offspring and MDCS cohorts (N=2180) identified 76 of the 120 pQTLs (63.3%) that reached a Bonferroni-adjusted level of significance (P≤3.2×10 -10 ) ( Table II in the online-only Data Supplement, columns R-T).
For the 85 proteins that had an identified genetic locus, almost half (38 proteins [44.7%]) had an associated genetic variant (or variant in strong linkage disequilibrium (LD) with r 2 >0.8) that mapped to the coding gene for that protein ( Figure 3B ). Forty-seven proteins (55.3%) had an associated genetic variant in cis (<1 megabase pairs) to the coding gene for the measured protein. The majority of pQTLs (and associated variants in LD) were located in noncoding regions of the genome. The sentinel SNP for 3 pQTLs was predicted to encode either a missense or synonymous substitution, and 15 additional sentinel SNPs (13.0%) were noted to be in strong linkage disequilibrium (r 2 >0.8) with predicted missense mutations. More than half (60%) of the identified pQTLs appeared to be novel (Table II in the online-only Data Supplement, columns U-X). [23] [24] [25] These included novel cis pQTLs for key proteins involved in extracellular matrix homeostasis (eg, thrombospondin-2, SNP rs73043837; extracellular matrix protein 1, SNP rs72704686) and inflammation (eg, complement factor B, SNP rs522162; complement C2, sentinel SNP rs115204832; and the soluble advanced glycosylation end product-specific receptor, sentinel SNP rs144769310). Dozens of novel trans pQTLs for disease-associated proteins were identified, including examples that strongly validated in MDCS (eg, aryl-hydrocarbon receptor-interacting protein, SNP rs13469; laminin, chr 20:60948294:ATC/A; and lymphatic vessel endothelial hyaluronic acid receptor 1, chr 11:126226554:GGAGT).
Overlap Between pQTL and Cardiovascular Genetic Risk Loci From Large Consortium Studies
Proteins associated with CVD risk loci may be disease biomarkers or pathway intermediates that contribute to CVD pathophysiology. Four pQTLs overlapped with coronary artery disease or myocardial infarction risk loci previously identified in the CARDIoGRAMplusC4D consortium 19 (with Bonferroni-adjusted levels of significance (P≤0.05/120=4.2×10 -4 ) ( Table III in the online-only Data Supplement). These findings validated a novel pQTL for interleukin-1 receptor type 1 (sentinel SNP rs11682107, prior P=1.2×10 -4 ), 24 a cytokine receptor that mediates the atherogenic effects of interleukin-1 26 and overlapped with a known risk locus for myocardial infarction (P=3.4×10 -5 ). Consistent with this in silico finding, elevated plasma levels of interleukin-1 receptor type 1 have been documented in individuals with evidence of obstructive coronary artery disease. 27 Similarly, these findings identified a novel pQTL for α-1-antitrypsin (sentinel SNP rs112635299), a serineprotease inhibitor detected in human atherosclerotic coronary lesions and associated with angiographic progression of coronary artery disease, 28 which overlapped with a known risk locus for coronary artery disease 
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(P=3.9×10 -4 ). Additional examples in which pQTLs can be used to clarify risk locus annotations in metabolic diseases are discussed below.
Exome Array Analyses Identify Functional Exonic Variants Associated With the Plasma Cardiovascular Disease Risk Proteome
Relationships between the 156 FRS-correlated proteins and functionally relevant exome variants were next analyzed on the Illumina HumanExome Beadchip. Analyses were restricted to polymorphic variants that were predicted to result in nonsynonymous, stop-altering, or splice-altering substitutions. Thirteen single-variant protein associations were identified between 13 loci and 10 proteins that reached a Bonferroni-adjusted level of statistical significance (P≤0.05/81 021 variants included on the exome chip array = 6.2×10 -7 ) ( Table IV in To capture additional low-frequency functional exonic variant-protein associations, gene-based burden testing was performed. 16 Analysis was restricted to include only polymorphic variants that were predicted to be damaging missense, stop-altering, or splice-altering substitutions. In total, 28 gene-protein associations were identified between 23 genes and 23 proteins that reached a Bonferroni-adjusted level of statistical significance using linear mixed-effects models (P≤0.05/13 008 total number of genes tested = 3.8×10 -6 ) (Table V in the online-only Data Supplement). Nineteen of the associations (67.9%) validated with Bonferroni-adjusted levels of significance (Table V in the online-only Data Supplement), and every validated association demonstrated similar magnitude and direction of effect between FHS and MDCS ( Figure 3A, inset) . This analysis identified 17 additional genes associated with plasma proteins that were not identified in the single-variant exome array analyses. Similarly, this burden testing identified genetic associations for 15 additional proteins as compared with single-variant exome analyses (7 of which did not also have genetic associations in the genome-wide analyses). Consistent with genome-wide and singlevariant exome array analyses, 12 of the associations (42.8%) mapped to the gene that encoded the associated protein, and 16 of the associations (57.1%), were located in cis. Several novel trans associations were detected that may provide insight into CVD pathogenesis. For example, a pQTL was identified for the advanced (association between rs3816018 at 5q32 and levels of platelet-derived growth factor receptor-β). B, Ideogram demonstrating pQTLs derived from GWAS and exome array analyses. Overlapping CVD risk loci from consortium studies are shown (Bonferroni significance P≤0.05/120≤4.2×10 -4 ). Ideogram generated using NCBI Genome Decoration Page. CAD indicates coronary artery disease; CVD, cardiovascular disease; FRS, Framingham CVD Risk Score; GWAS, genome-wide association study; NCBI, National Center for Biotechnology Information; pQTL, protein quantitative trait loci; and SNP, single-nucleotide polymorphism.
glycosylation end product-specific receptor, a ligandreceptor pathway that is suspected to play a key role in early atherogenesis in patients with diabetes mellitus, 29 that mapped to the α-(1,6)-fucosyltransferase enzyme. By linking a fucosyltransferase with the advanced glycosylation end product-specific glycoprotein receptor, this trans association identified a biologically plausible potential novel point of regulation in the ligand-receptor axis.
Experimental Validation of a Novel ApoE pQTL in a Human Liver Cell Model
To identify central pathways that regulate the human plasma CVD risk proteome, we searched for genetic variants that had associations with multiple protein levels. Three pleiotropic variants were identified that each had strong independent correlations with 5 different plasma proteins (P≤1×10 -5 , Pearson correlations between proteins associated to a single SNP ≤0.60) ( Figure 4A ). Consistent with our hypothesis that pleiotropic variants may encode central protein expression machinery, each of these variants tagged a nearby gene (PPM1G, FOXP1, and FAM20A) known to regulate the transcription 7, 30 or secretion 31 of proteins. One variant (rs1728918) was of particular interest because it resides in a genomic locus associated with circulating total cholesterol levels (P=7.7×10 -9 ). 21 This variant, also associated with circulating levels of ApoE in trans in our dataset, mapped to the nuclear phosphatase PPM1G. This gene governs transcription elongation 7 and, to our knowledge, has not previously been tied to plasma ApoE regulation.
To directly test the causal role of PPM1G in regulating ApoE expression and secretion levels, we used small-interfering RNA to knock down endogenous levels of PPM1G in the Hep G2 human liver hepatocellular carcinoma cell line and then measured ApoE expression levels by reverse-transcription polymerase chain reactions and ApoE protein accumulation in the culture media by ELISA. As shown in Figure 4B , knockdown of endogenous PPM1G by ≈90% (P=8×10 -7 ) resulted in a significant 35.9% reduction in ApoE expression (P=6.0×10 -3 ). The effect of PPM1G knockdown was specific and had no significant effect on expression levels of multiple housekeeping genes, including polyubiquitin-C (2.8% increase, P=0.86). Further, knockdown of PPM1G also resulted in a significant and specific 20% reduction in levels of ApoE accumulating in the culture media (P=1.6×10 -6 ), with no appreciable effect on lev- ) and 28 variants identified by exome array burden testing analyses (crosses; Bonferroni-adjusted level of significance P=1.8×10 -3 ). B, pQTLs are shown as a function of distance from the coding gene for the associated plasma protein in genome-wide analyses (left) and exome array single-variant analyses (right). pQTLs were considered to be in cis to the coding gene for the associated protein when they were located ≤1 Mb from the coding gene transcriptional start site. pQTLs were considered to be in trans if the associated coding gene was located on the same chromosome ≥1 Mb or on a different chromosome (Inter-Chrom). The statistical strength of validation of each pQTL is shown as in A. EC indicates exome chip; FHS, Framingham Heart Study; GWAS, genome-wide association study; Mb, megabase; MDCS, Malmö Diet and Cancer Study; and pQTL, protein quantitative trait loci.
ORIGINAL RESEARCH ARTICLE
els of macrophage migration inhibitory factor, which was used as a negative control (0.6% decrease, P=0.94) ( Figure 4C ). Taken together, these data experimentally validate the identification of PPM1G as a novel regulator of ApoE levels and provide proof-of-principle that GWASs of protein intermediates can provide valuable insight to novel regulatory pathways that underlie the CVD risk proteome.
PPM1G Pathway Analyses
To identify a potential mechanism that underlies the pleiotropic effects of PPM1G, pathway enrichment analyses on each of the 5 proteins associated with the PPM1G locus were performed (Ingenuity Pathway Analysis software). Four of the 5 proteins associated with the PPM1G locus were known to either regulate or be regulated by the effects of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), 32-34 a transcription factor involved in the response to chronic inflammation and atherosclerotic CVD. 35 PPM1G is specifically recruited to NF-κB target gene promoters to facilitate transcriptional pause release in response to extrinsic stimuli such as genotoxic stress and inflammation. PPM1G dephosphorylates the inhibitory 7SK small nuclear ribonucleoprotein complex and releases paused DNA polymerase II to allow for transcriptional elongation. 7 As shown in Figure I in the online-only Data Supplement, these bioinformatic observations suggest a model by which PPM1G is recruited to NF-κB target gene promoters to release 7SK small nuclear ribonucleoprotein-mediated transcriptional inhibition and allow for the expression of NF-κB target genes, such as ApoE, 33 gelsolin, 32 and contactin-1. 34 Metalloproteinase inhibitor 2 is known to be a strong activator of NF-κB transcriptional activity through modulatory effects on the inhibitor of NF-κB.
36
Mendelian Randomization Exploratory Analyses
By tying genetic variants to circulating protein levels, the dataset of pQTLs provided a unique opportunity to use Mendelian randomization statistical methods to test the causal association of circulating proteins to selected clinical phenotypes. The sentinel SNP from each pQTL served as an instrumental variable to estimate the effect of the associated plasma protein on a range of clinical CVD risk factors (FRS, circulating high-density lipoprotein, circulating total cholesterol, systolic blood pressure, and diabetes mellitus). We focused our analyses on sentinel SNPs that were predicted to have large effect sizes on the associated protein (SNPs that explained ≥20% of the variance of the associated plasma protein level). It is important to note that these represent exploratory analyses because the study was not powered to evaluate associations between genetic variants and several of the clinical phenotypes. As shown in Figure II in the online-only Data Supplement, Mendelian randomization analyses were applied to 5 of the 11 proteins analyzed, and 8 examples in which Mendelian randomization supported a possible causal association A, Pleiotropic variants (ordered by physical location in the genome on the x-axis) were mapped against the number of distinct associations with CVD risk proteins (y-axis). A locus near the PPM1G gene was identified that was associated with 5 plasma CVD risk proteins, including ApoE. B, Knockdown of endogenous PPM1G in the Hep G2 cell line resulted in a significant reduction in endogenous ApoE expression, as measured by RT-PCR, but had no effect on levels of Ubc (negative control). C, Knockdown of endogenous PPM1G in Hep G2 cells also significantly reduced endogenous ApoE accumulation in the culture media as measured by ELISA but had no effect on culture media levels of MIF (negative control). P values represent the statistical significance of paired 2-sample t tests. ApoE indicates apolipoprotein E; CVD, cardiovascular disease; MIF, migration inhibitory factor; PPM1G, phosphatase 1G; RT-PCR, reverse-transcription polymerase chain reaction; siRNA, small-interfering RNA; and Ubc, Polyubiquitin-C. Figure II in the online-only Data Supplement). This finding suggested a potential causal association of circulating kynureninase with diabetes mellitus status, assigning direction of the association from protein to risk factor. Intriguingly, kynureninase catalyzes the hydrolysis of kynurenine to anthranilic acid in the tryptophan catabolism pathway. Prior studies have shown that both kynurenine and anthranilic acid are strongly associated with insulin resistance traits in humans, including the homeostatic model assessment of insulin resistance. 37 Associations between SNP and protein, protein and risk factor, or SNP and risk factor were not strong enough to allow for Mendelian randomization in the remaining instances.
DISCUSSION
The current study significantly expands the number of pQTLs that have been described to date in human plasma. We identified 120 locus-protein associations in genome-wide analyses, 13 locus-protein associations in single-variant exome array analyses, and 28 locus-protein associations in burden testing exome array analyses of specific interest in CVD research, the majority of which were novel. More than half (60%) of the pQTLs identified in the genome-wide analyses had not been identified in prior studies of human peripheral blood using a similar aptamer-based platform (Table II in the onlineonly Data Supplement, columns U-X), [23] [24] [25] likely owing to the relatively large derivation and validation sample sizes in the current study. Overall, heritability of proteins exceeded that of metabolites studied in the same cohort, suggesting that circulating metabolites may be more dependent on dietary and other environmental influences.
The great majority of loci provided new insight to mechanisms that may help govern circulating levels of each associated protein. For example, the pQTL for cathepsin S (sentinel SNP rs72702561), a cysteine protease localized to arterial wall smooth muscle cells and macrophages in human and mouse model atherosclerotic lesions and a serum marker of increased mortality in elderly individuals, 38 was in strong LD (r 2 =0.84), with a missense mutation predicted to result in a valine-toalanine substitution in the N-terminal signal peptide responsible for cathepsin S secretion efficiency. Similarly, the pQTL for ectonucleotide pyrophosphatase/ phosphodiesterase family member 7 (sentinel SNP rs11653614), a sphingomyelinase implicated in the regulation of intestinal cholesterol absorption, 39 was in strong LD (r 2 =0.94) with a missense mutation predicted to result in a proline-to-leucine residue change in the N-terminal secretion signal peptide for ectonucleotide pyrophosphatase/phosphodiesterase family member 7. The pQTL for alcohol dehydrogenase (nicotinamide adenine dinucleotide phosphate[+]) (sentinel SNP rs72688441), an aldo-keto reductase associated with the clinical development of daunorubicin-induced cardiotoxicity, 40 was in strong LD (r 2 =0.92), with a missense mutation predicted to result in an asparagine-to-serine mutation located between the Nicotinamide adenine dinucleotide phosphate-binding and active sites of the protein. Ligand binding, and in particular Nicotinamide adenine dinucleotide phosphate binding, has been well documented to affect alcohol dehydrogenase conformation and protein stability. 41 Several other examples of locus-protein associations located in trans offered insight into potential new connections between known CVD pathways. For example, using single-variant exome array analyses, we detected a novel pQTL located on chromosome 8 for plasma levels of galectin-3-binding protein, a known marker of carotid atherosclerosis and long-term mortality in coronary artery disease. 42 This pQTL was located in trans to the coding gene for galectin-3-binding protein (located on chromosome 17) but replicated strongly in MDCS (P=4.1×10 -20 ). The sentinel SNP for this pQTL was rs41341748, which was predicted to result in a nonsense arginine-to-glycine mutation in the collagen triple-helix motif of macrophage scavenger receptor type I protein. Thus, this locus-protein correlation identified a possible novel biological tie between macrophage scavenger receptor type I glycoprotein located on the macrophage membrane and the macrophage lectin binding activity of galectin-3-binding protein.
Novel locus-protein associations can also provide valuable insight into the annotation of cardiometabolic risk loci. The majority of variants tied to CVD in consortium studies are located in noncoding regions of the genome. 6 Linking these variants to intermediate phenotypes, such as protein expression data, can help map the functional associations around these variants and identify candidate causal genes in the pathophysiology of CVD. For example, the SNP rs2612012 has been strongly correlated with BMI in large-scale, GWAS consortium meta-analyses 43 and has implicated the potential involvement of the Cav1.3 L-type calcium channel in BMI pathogenesis because this SNP is located within an intron of the Cav1.3 L-type calcium channel gene and has no nearby related variants in strong LD (r 2 ≥0.3). Notably, we identified a strong association between this SNP and plasma levels of the interleukin-17 receptor B (P=1.1×10 -6 , estimated β-coefficient -0.29), a plasma protein previously identified to have a strong inverse correlation with BMI (P≤9.6×10 -6 in both FHS and MDCS). As with all affinity-based proteomic tools, the specificity of aptamer reagents must be validated. We and others have developed several mass spectrometry methods for target validation, but throughput remains a challenge with these strategies. 3, 44 By correlating genomic variants located in or near the coding gene for the measured protein, we were able to systematically investigate aptamer target specificity for a number of analytes in this study. We found that for the 94 proteins with an associated genetic locus identified through either genome-wide, single-variant exome array analyses or burden testing exome array analyses, ≈50% had an associated genetic variant (or variant in strong LD with r 2 >0.8) that mapped to the coding gene for that protein. Fifty proteins (53.2%) had an associated genetic variant in cis to the coding gene for the measured protein. Taken together, these findings help validate many of the specific aptamer targets included in this study and provide a strategy for systematically validating affinity-based reagent specificity in proteomic discovery. 2 Analysis of locus-protein associations that are located in trans provides a rich, nonbiased strategy to connect individual molecular components into novel biological pathways that may contribute to disease pathophysiology. Strikingly, and consistent with our hypothesis that pleiotropic loci may highlight central protein expression machinery, the most pleiotropic variants tagged a nearby gene (PPM1G, FOXP1, and FAM20A) known to regulate transcription 7, 30 or secretion 31 of proteins. One of these variants (rs1728918) was of particular interest because it was associated with circulating levels of ApoE and is located in a genomic region linked to circulating total cholesterol levels. 21 This SNP lies in a noncoding region of the genome most closely located to the gene for the nuclear PPM1G, a serine/threonine protein phosphatase that governs transcription elongation. 7 To our knowledge, PPM1G has not previously been recognized to participate in lipid metabolism. By using ApoE levels as an experimental readout, we were able to link PPM1G to lipid biology. This identifies PPM1G as a gene that may now warrant more extensive, targeted functional investigation.
This study had several important limitations. Although our analyses included a discovery and validation cohort, the total number of individuals was relatively small. Although reasonably well powered to detect common (MAF>5%) and low-frequency variants (0.5%<MAF≤5%), our analyses were less powered to detect rare variants (MAF≤0.5%) that may have additional important contributions to the CVD risk proteome. Exome array gene-based burden testing partially addressed this limitation, although additional low-frequency and rare variants may have not been completely captured by these analyses. It is also important to note that the FHS and MDCS cohorts were predominately of European decent. As the throughput and cost of broadscale protein profiling continues to improve, it will be important to confirm and expand these results in larger and more ethnically diverse sample cohorts. Although the aptamer-based platform that we used to identify the plasma CVD risk proteome of 156 proteins covered 1129 total proteins, its coverage of the global proteome remains limited and does not capture the effects of posttranslational modifications and other analytes important in CVD pathogenesis. Prior work suggests that nonspecific binding to aptamer reagents, variations in the composition of test samples, and sample handling can affect aptamer-based proteomic results. 45 As is the case with all affinity-based proteomic assays, protein targets of interest that are identified using an aptamer-based platform must be validated using orthogonal technologies, such as mass spectrometry, as previously described. 3 In summary, we have identified a broad dataset of genetic locus-protein relationships that are of special relevance to CVD biology. Although these analyses highlighted several specific locus-protein correlations of interest and experimentally validated a particularly novel genetic association with plasma ApoE levels, further interrogation of these data should provide additional insights. Locus-protein associations that did not meet a Bonferroni-adjusted level of significance when analyzed as a complete dataset may be highly informative when studied in the context of a single protein or gene of interest, for example. Because all variant-protein associations are being made publically available, investigators can leverage this resource to further study particular genes or circulating proteins of interest in an array of cardiometabolic and other disease contexts.
ARTICLE INFORMATION
Received May 16, 2017; accepted November 6, 2017.
The online-only Data Supplement is available with this article at http://circ. ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.029536/-/ DC1.
